Online Only Articles

Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria
Department of Laboratory Medicine, Medical University of Vienna, Austria
Blood Transfusion Service for Upper Austria, Austrian Red Cross, Linz, Austria
3rd Medical Department, Hanusch Hospital, Vienna, Austria
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
Department of Laboratory Medicine, Medical University of Vienna, Austria
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria
Vol. 101 No. 12 (2016): December, 2016 https://doi.org/10.3324/haematol.2016.156448